Clinical Trials and Research
-
5/7/12 7:00 am MDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) ("Company" or "BSD") (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, reported today that an important Phase III clinical study,
hyperthermia in combination with chemotherapy for the treatment of
pancreatic cancer patients, was the subject of a press release issued by
The Society of Thermal Medicine (STM) (http://psfebus.allenpress.com/eBusSFTM/).
STMmore...
-
4/23/12 7:00 am MDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, announced today that a scientific poster presented at the
Society of Interventional Radiology (SIR) conference, featuring data
generated using the MicroThermX® Microwave Ablation System
(MicroThermX®), demonstrated a significant advantage for
MicroThermX® microwave ablation. The study, "more...
-
2/21/12 7:00 am MST
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) reports initiation of a
randomized, multicenter, Phase III clinical study using the BSD-2000
Hyperthermia System to deliver hyperthermia in combination with
chemotherapy for the treatment of pancreatic cancer patients. The Phase
III study, which is being sponsored by the European Society for
Hyperthermic Oncology (ESHO), will compare hyperthermia with
chemotherapy (gemcitabine plus cisplatin) to chemotherapymore...
-
11/1/11 7:00 am MDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, today reported that the recently issued "National Clinical
Practice Guidelines in Oncology for Soft Tissue Sarcoma" (V.2.2011),
issued by the National Comprehensive Cancer Network (NCCN), expands the
recommendations for the use of hyperthermia and chemotherapy as a cancer
treatment tomore...
-
10/12/11 8:00 am MDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems that utilize targeted heat therapy to treat cancer, today reported that study results demonstrate a survival benefit, without an increase in toxicity, from the addition of hyperthermia (HT) for the treatment of advanced pancreatic cancer patients. The study, "Regional Hyperthermia Combined with Chemoradiotherapy in Primary or Recurrent Locally Advanced Pancreatic Cancer" (more...
-
6/20/11 7:00 am MDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, today announced that the clinical role of hyperthermia was the
focus at the annual European Society for Hyperthermic Oncology (ESHO)
Meeting, which was held in Aarhus, Denmark, May 26-28, 2011. The 27th
annual ESHO meeting was held in conjunction with the 20th
annual European BSD Usersmore...
-
6/10/11 7:00 am MDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, announced today that a study published in the Proceedings of
the National Academy of Sciences demonstrated that hyperthermia can
be a powerful tool to inhibit the ability of cancer cells to repair the
DNA damage caused by radiation or chemotherapy. The researchers reported
that the findingsmore...
-
6/3/11 7:00 am MDT
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, today announced that the clinical role of hyperthermia was the
focus at the annual European Society for Hyperthermic Oncology (ESHO)
Meeting, which was held in Aarhus, Denmark, May 26-28, 2011. The 27th
annual ESHO meeting was held in conjunction with the 20th
annual European BSD Usersmore...
-
2/24/11 7:00 am MST
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) today announced
the inclusion of hyperthermia and chemotherapy as a recommended cancer
treatment for Stage IV (metastatic) sarcomas in the "Practice Guidelines
in Oncology" (V.2.2010), which is issued by the National Comprehensive
Cancer Network (NCCN). NCCN is a not-for-profit alliance
of 21 of the world’s leading cancer centers, and its practice
guidelines are a benchmark for clinicalmore...
-
2/7/11 7:00 am MST
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (BSD or the Company) today
reported publication of an article on BSD’s pioneering development of
sophisticated technology to improve the delivery of heat therapy for the
treatment of certain cancerous tumors. The article, “Interstitial
microwave transition from hyperthermia to ablation: Historical
perspectives and current trends in thermal therapy,” which was authored
by TP Ryan, PF Turner, and B Hamilton,more...
